GAITHERSBURG, Md. (Reuters) – A veteran scientist at the U.S. Food and Drug Administration said on Wednesday that he will present new, as-yet-unpublished findings about heart risk in a number of pain drugs at a meeting to assess whether they are safe enough for patients.
David Graham, associate director for science and medicine at the FDA’s Office of Drug Safety, said he decided to talk about the findings after FDA Acting Commissioner Lester Crawford sent a letter saying he could do so without fear of reprisal. Graham had earlier said he would not present the data after he felt threatened by supervisors.
FAIR USE NOTICE: This may contain copyrighted (©) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.